Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 1 of 1 entries
View as:
Phase: N/A
Priority: Normal
Start: 05/31/25
End: 09/30/28
Due: 09/30/29
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Pembrolizumab + Paclitaxel +/- Bevacizumab for Triple-negative Breast Cancer | NCT06976944 | Yukinori Ozaki | user2@example.com | None | 2025-05-31 | 2028-09-30 | 2029-09-30 | - | - | 2025-07-14 |